Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 24;21(12):67.
doi: 10.1007/s11910-021-01153-8.

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021

Alejandro Perez  1 , Jason T Huse  2
Affiliations
Review

The Evolving Classification of Diffuse Gliomas: World Health Organization Updates for 2021

Alejandro Perez et al. Curr Neurol Neurosci Rep. .

Abstract

Purpose of review: The upcoming 2021 World Health Organization (WHO) Classification of Tumours of the Central Nervous System will feature numerous changes in classification, diagnostic criteria, nomenclature, and grading of diffuse gliomas. This article reviews these changes and the clinical and molecular findings underlying them.

Recent findings: Since the publication of the 2016 World Health Organization (WHO) Classification of Tumours of the Central Nervous System, research has led to new insights into how molecular changes impact both the classification and grading of CNS tumors. The continued integration of molecular and histopathological features has led to changes in diagnostic criteria and grading for various tumors. In the new 2021 WHO CNS tumor classification scheme, diffuse gliomas will be classified as either adult-type diffuse gliomas, pediatric-type diffuse high-grade gliomas, or pediatric-type diffuse low-grade gliomas. The upcoming changes in the classification of adult-type and pediatric-type diffuse gliomas allow for more effective communication of both diagnostic and prognostic information, and-particularly in the case of pediatric-type diffuse gliomas-may suggest possible targeted strategies for therapeutic intervention.

Keywords: Adult; Diffuse glioma; Genomics; Molecular; Pediatric; World Health Organization.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. •• Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, et al. cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020;30(4):844–56. https://doi.org/10.1111/bpa.12832 . This article details recommendations for the upcoming WHO 2021 Classification of CNS Neoplasms, including refined diagnostic classes and conversion to Arabic numerals for grading. - DOI - PubMed - PMC
    1. Brat DJ, Aldape K, Colman H, Figrarella-Branger D, Fuller GN, Giannini C, et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. Acta Neuropathol. 2020;139(3):603–8. https://doi.org/10.1007/s00401-020-02127-9 . - DOI - PubMed - PMC
    1. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Ellison DW, Figarella-Branger D et al. WHO Classification of Tumors of the Central Nervous System. World Health Organization Classification of Tumours. Lyon: International Agency for Research on Cancer; 2016.
    1. Aoki K, Nakamura H, Suzuki H, Matsuo K, Kataoka K, Shimamura T, et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas. Neuro Oncol. 2018;20(1):66–77. https://doi.org/10.1093/neuonc/nox132 . - DOI - PubMed
    1. • Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol. 2019;21(12):1519–28. https://doi.org/10.1093/neuonc/noz124 . This article identifies CDKN2A deletion as a robust prognostic marker in IDH-mutant astrocytoma. - DOI - PubMed - PMC

LinkOut - more resources